Compare KT & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KT | PEN |
|---|---|---|
| Founded | 1981 | 2004 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 12.9B |
| IPO Year | 2002 | 2015 |
| Metric | KT | PEN |
|---|---|---|
| Price | $21.97 | $329.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $357.33 |
| AVG Volume (30 Days) | ★ 1.2M | 499.3K |
| Earning Date | 02-10-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | N/A | ★ 4.52 |
| Revenue | N/A | ★ $1,403,665,000.00 |
| Revenue This Year | N/A | $14.34 |
| Revenue Next Year | $2.03 | $13.71 |
| P/E Ratio | ★ $15.73 | $73.54 |
| Revenue Growth | N/A | ★ 17.50 |
| 52 Week Low | $17.54 | $221.26 |
| 52 Week High | $24.58 | $362.41 |
| Indicator | KT | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 39.29 |
| Support Level | $21.36 | $326.58 |
| Resistance Level | $24.58 | $338.99 |
| Average True Range (ATR) | 0.40 | 2.12 |
| MACD | 0.08 | 0.26 |
| Stochastic Oscillator | 48.01 | 27.52 |
KT is South Korea's largest fixed-line telecom operator, with around 11.5 million fixed-line broadband customers and 9.5 million IPTV customers, and is the second-largest wireless operator with 28 million subscribers. Additionally, it has a number of nontelecom businesses, including real estate, payment processing, artificial intelligence, and IDC/cloud services, many of which are the focus of its growth strategy. The company was formed from the previously government-owned, monopoly telecom business and was listed in 1998. After selling its mobile business in 1994 (forming its mobile competitor, SK Telecom), KT created its own mobile operator in 1997.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.